Lung Cancer

Perioperative Nivolumab Preserves Quality of Life in Resectable NSCLC, WCLC 2025 Data Show

New patient-reported outcomes at WCLC 2025 confirm preserved quality of life with the FDA-approved perioperative nivolumab regimen.